Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific antibody, plus chemotherapy with or without the PD-1 inhibitor tislelizumab vs trastuzumab plus chemotherapy as first line-regimens for HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Abstract LBA285).
Marcel Verheij, MD, PhD, of Radboud University Medical Center, presents findings from the phase II CRITICS-II trial, which compared three preoperative regimens while omitting adjuvant treatment among patients with nonmetastatic resectable gastric cancer: chemotherapy, chemotherapy followed by chemoradiotherapy, and chemoradiotherapy (Abstract 283).
Matthew Strickland, MD, of Massachusetts General Hospital, reviews results from the phase IIb TERRIFIC trial, which compared the efficacy and safety of the PD-1 inhibitor tislelizumab plus chemoradiotherapy vs chemoradiotherapy or chemotherapy alone in the neoadjuvant treatment of patients with gastric or gastroesophageal junction adenocarcinoma (Abstract 286).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as first-line treatment for unresectable hepatocellular carcinoma (Abstract TPS612).
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma (Abstract LBA284).
